US+1 646-781-8004

HomeBlog Details

Meticulous Research®

The name of our company defines our services, strengths, and values. Since the inception, we have endeavoured to research, analyze and present the critical market data with great attention to details.

Expansion & Acquisition of Plasma Collection Centers Boosts Plasma Fractionation Market Globally

   September 21, 2022

Plasma collection centers are the main source of plasma for the plasma fractionation plants. As plasma collection centers increases, the more liters of plasma will be fractionated by the companies and hence the more plasma derived products will be available for the countries. According to the KEDRION GROUP 2018 data, the plasma collection centers in the U.S. increased from 929 in 2020 to 877 in 2019. Also, the plasma collection centers in Europe increased from 93 in 2015 to 143 in 2019.

Apart from this, recently, companies are acquiring or opening new plasma centers across various countries. For instance;

  • In March 2021, Grifols S.A. (Spain)acquired 25 U.S.-based plasma centers from BPL(U.S.) to promote global expansion.
  • In July 2020, Grifols S.A. (Spain)acquired Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.based plasma collection centers.
  • In December 2019, Biotest AG (Germany)opened its fourth plasma collection centre in Czech Republic. Also, in April 2019, the company opened its ninth plasma collection centre in Hungary.
  • In October 2018, Shire plc (Republic of Ireland)did its second submission to the U.S. FDA for its new plasma manufacturing facility near Covington, Georgia. This plant helps to manufacture FLEXBUMIN.
  • In February 2018, China Biologic Products Holdings, Inc. (China)opened plasma collection station in Hainan Province.
  • In March 2018, ImmunoTek Bio Centers LLC (U.S)opened its 20thPlasma Collection Center in the U.S.

Thus, such growing investments of vendors in opening new plasma centers would certainly help the global plasma fractionation market surge ahead in near future.

During COVID-19, this trend increases a lot. For instance,

  • According to the August 2020 news, Kedrion Biopharma (Italy) started the development of a plasma-derived therapy for treating the COVID-19 virus infection that could make it available to patients in as little as three to six months. The company is working in close collaboration with hospitals from some of the most COVID infected regions of Italy.
  • In June 2020, Kamada Ltd. (Israel) completed manufacturing and released the first batch of its plasma-derived Hyper-immune IgG product for COVID-19 and it is available for compassionate use treatment in Israel.

Expansion of such centers raises the usage of immunoglobulins (largest extracted substance from plasma) for various therapeutic areas.

This is expected to drive the global plasma fractionation marketat CAGR of 7.1% to reach $46.9 billion by 2029, according to the Meticulous Research®.

Access Full Report Here:

Related Tag:

Related Blogs:

Meticulous Research
+1 646-781-8004
Meticulous Research
Meticulous Research
Subscribe to get the latest industry updates